Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2018-12-11 AGM Information
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Kallelse till extra bolagsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is titled "Kallelse till extra bolagsstämma i NeuroVive Pharmaceutical AB (publ)" which translates to "Notice of Extraordinary General Meeting in NeuroVive Pharmaceutical AB (publ)". It details the date, time, location, registration procedures, agenda items (including proposals for a rights issue and changes to the articles of association), and voting requirements for an upcoming shareholder meeting. This content directly corresponds to the purpose of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) notice/materials. Since the definition for AGM-R covers "Presentations and materials shared during the Annual General Meeting (AGM)", and this is the formal notice calling for an EGM, AGM-R is the most appropriate classification, as it covers general shareholder meeting documentation. It is not a DEF 14A (Remuneration) or DVA (Voting Results), but the call itself.
2018-12-11 Swedish
Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)". It details the date, time, location, procedures for participation (including proxy rules), the proposed agenda, and specific resolutions to be voted upon, such as a rights issue (share issuance) and amendments to the articles of association. This content is characteristic of materials distributed to shareholders in advance of a general meeting to inform them and solicit their votes. This aligns perfectly with the definition of materials shared during an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM). Since the definitions include 'AGM Information (Code: AGM-R)' for presentations and materials shared during the AGM, this is the most appropriate classification, even though it is an 'Extraordinary' meeting, as the core function is the same as an AGM's preparatory material.
2018-12-11 English
Kallelse till extra bolagsstämma i NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is titled "Kallelse till extra bolagsstämma i NeuroVive Pharmaceutical AB (publ)" which translates to "Notice of Extraordinary General Meeting in NeuroVive Pharmaceutical AB (publ)". It details the date, time, location, registration procedures, agenda items (including proposals for a rights issue and changes to the articles of association), and voting requirements for an upcoming shareholder meeting. This content directly corresponds to the purpose of a notice for a general meeting, which is closely related to the materials distributed to solicit votes or provide information ahead of such a meeting. While it is not a Proxy Statement (PSI) or a Declaration of Voting Results (DVA), the core function is calling shareholders to a meeting. The closest fit among the provided codes is AGM-R (AGM Information), as an Extraordinary General Meeting (EGM) notice shares the same fundamental purpose as AGM materials—convening shareholders for corporate decisions. Given the context of calling a meeting and presenting proposals, AGM-R is the most appropriate classification, even though it is a 'Notice' rather than the 'Presentation' itself, as there is no specific code for an EGM Notice, and AGM-R covers general meeting materials.
2018-12-10 Swedish
Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "Notice of Extraordinary General Meeting of NeuroVive Pharmaceutical AB (publ)". It details the date, time, location, entitlement requirements, agenda items (including election of chair, approval of agenda, and resolutions on share issuance and articles of association amendments), and procedures for an Extraordinary General Meeting (EGM). This content directly corresponds to the purpose of an AGM/EGM notice or related materials. Since the options include 'AGM-R' (AGM Information) and the document is a notice/material for a general meeting, AGM-R is the most appropriate classification, even though it is an EGM notice, as it covers general meeting materials.
2018-12-10 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the period January-September 2018 for NeuroVive Pharmaceutical AB. It contains detailed financial performance data (income statements, earnings per share), management commentary, and updates on research and development projects. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. 9M 2018
2018-11-22 Swedish
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Interim report January - September 2018' and contains detailed financial statements (Net revenues, Loss before tax, Loss per share) for both the third quarter and the first nine months of 2018. It also includes extensive management commentary, project status updates, and operational highlights. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. 9M 2018
2018-11-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.